首页 产品目录 全部产品 雷莫芦单抗

雷莫芦单抗

Ramucirumab

产品编号 :
Cas No. :
包装规格 纯度 目录价 会员专享价 库存 数量

抱歉,暂无牌价信息

晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。

基础信息

CAS No.

947687-13-0

中文名称

雷莫芦单抗

英文名称

Ramucirumab

别名

Ramucirumab;Ramucirumab,NSCLC,non–small-cell lung cancer,gastric cancer,Inhibitor,VEGFR,Vascular endothelial growth factor receptor,inhibit,angiogenesis inhibitor;Cyramza;IMC-1121B;LY3009806;Ramucirumab (anti-VEGFR2);Ramucirumab (anti-VEGFR)

标准英文名

silver

MDL No.

MFCD01092518

分子式

Ag13

分子量

1402.28

精确分子量

1389.77

SMILES

[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag]

标准SMILES

[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag].[Ag]

用途

Ramucirumab is indicated for: 1. The treatment of advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression during or after fluoropyrimidine- or platinum-containing chemotherapy, as monotherapy or in combination with paclitaxel. 2. The treatment of metastatic non-small cell lung cancer (NSCLC) with disease progression during or after platinum-based chemotherapy, in combination with docetaxel. 3. The treatment of metastatic colorectal cancer (mCRC) with disease progression during or after bevacizumab, oxaliplatin, and fluoropyrimidine-based chemotherapy, in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil). 4. As the first FDA-approved biomarker-driven therapy for hepatocellular carcinoma (approved in May 2019).

InChIKey

JPWNEBNBYYVUBY-UHFFFAOYSA-N

安全信息

SureRoute逆合成路线

1.  947687-13-0 逆合成路线 1

ACSCXG479
25503-90-6
ACHPRU325
947687-13-0
来源: SureRoute

2.  947687-13-0 逆合成路线 2

ACLIJC472
712270-40-1
ACHPRU325
947687-13-0
来源: SureRoute

3.  947687-13-0 逆合成路线 3

—
—
ACHPRU325
947687-13-0
来源: SureRoute
评论 0
我是晶智Agent,
您的化学小助手